Buprenorphine

"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Descriptor ID	D002047
MeSH Number(s)	D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
Concept/Terms	Buprenorphine Buprenorphine Buprenex Buprenex Prefin Prefin Subutex Subutex Buprex Temgesic Temgésic 6029-M 6029-M 6029 M 6029M RX-6029-M RX 6029 M RX6029M Buprenorphine Hydrochloride Buprenorphine Hydrochloride Hydrochloride, Buprenorphine

Below are MeSH descriptors whose meaning is more general than "Buprenorphine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Buprenorphine [D03.132.577.249.150]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Buprenorphine [D03.605.497.150]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Buprenorphine [D03.633.400.686.150]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Buprenorphine [D04.615.723.795.150]

Below are MeSH descriptors whose meaning is related to "Buprenorphine".

Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".

Buprenorphine
Buprenorphine, Naloxone Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.

Bar chart showing 47 publications over 17 distinct years, with a maximum of 6 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2004	1	0	1
2005	2	0	2
2007	2	0	2
2008	3	0	3
2009	3	0	3
2010	6	0	6
2011	2	1	3
2012	1	0	1
2016	2	0	2
2017	1	1	2
2019	1	0	1
2020	3	0	3
2021	3	1	4
2022	4	0	4
2023	4	0	4
2024	4	1	5

Below are the most recent publications written about "Buprenorphine" by people in Profiles.

Reed MK, Camacho TE, Gillingham J, Gill S, Gannon M, Abatemarco D, Kelly EL, Weinstein LC. Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA. J Subst Use Addict Treat. 2024 12; 167:209509.

View in: PubMed
Roth E, Bingaman A, Stern S, McKeever R, D'Orazio J, Schlosser SP, Cheng K, Zhao H, Anderson JH. Buprenorphine Induction in Trauma Patients With Opioid Use Disorder - A Single Center Experience? J Surg Res. 2024 09; 301:686-695.

View in: PubMed
Anbalagan S, Anderson V, Favara MT, Stark D, Carola D, Solarin K, Adeniyi-Jones S, Kraft WK, Aghai ZH. Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study. J Perinatol. 2025 Apr; 45(4):473-479.

View in: PubMed
Mallinson DC, Kuo HD, Kirby RS, Wang Y, Berger LM, Ehrenthal DB. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018. Prev Med. 2024 04; 181:107914.

View in: PubMed
Hagan L, David EM, Horton AR, Marx JO. Effects of Midazolam/Dexmedetomidine with Buprenorphine or Extended-release Buprenorphine Anesthesia in C57BL/6 Mice. J Am Assoc Lab Anim Sci. 2024 03 01; 63(2):172-181.

View in: PubMed
Gannon M, Hand D, Short V, McLaughlin K, Flood T, Shaffer K, Lenegan N, Abatemarco D, DiDonato S. Maternal Perspective of Inpatient Methadone Initiation: Opportunities to Increase Retention in Treatment. J Addict Med. 2024 Mar-Apr 01; 18(2):122-128.

View in: PubMed
Stern SJ, D'Orazio JL, Work BD, Calcaterra SL, Thakrar AP. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal? J Hosp Med. 2024 04; 19(4):339-343.

View in: PubMed
Prince E, Loeser P, Early M, Carroll CP, Lanzkron S, Pecker LH. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain. J Pain. 2024 03; 25(3):632-641.

View in: PubMed
Ahmed S, Faruqui Z, Poddar K, Bhivandkar S, Suzuki J. Low-dose buprenorphine initiation in the era of fentanyl and fentanyl analogs: A case series of outpatient inductions. J Opioid Manag. 2023 Sep-Oct; 19(5):455-460.

View in: PubMed
David MS, Jones J, Lauriello A, Nnake I, Plazas Montana M, Lasko K, Buri-Nagua C, Olagbaju Y, Williams E, Sears M, Salzberg B, Lanzkron SM, Carroll CP. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization. Am J Hematol. 2022 11; 97(11):1435-1442.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement